Lonza Group (LZAGY) Stock Price, News & Analysis

Company Overview

Lonza Group AG, together with its subsidiaries, supplies various products and services for pharmaceutical, biotech, and nutrition markets in Europe, North and Central America, Latin America, Asia, Australia, New Zealand, and internationally. It operates through Biologics, Small Molecules, Cell & Gene, and Capsules & Health Ingredients segments. The Biologics segment engages in the contract development and manufacturing of biopharmaceuticals for clinical and commercial manufacturing needs throughout the product lifecycle, including drug substance and drug product manufacturing. The Small Molecules segment operates as an integrated development and manufacturing service provider for small molecule drug substances and their intermediates. This segment also supports customers across various aspects of design, development, and manufacturing, including particle engineering and drug product packaging. The Cell & Gene segment develops technologies and platforms that industrialize the manufacturing processes and production of cell and gene therapies; offers contract development and manufacturing services, and regulatory support for a range of allogeneic and autologous cell therapies, and exosome-based therapies, as well as viral vector gene therapies. This segment also provides Cocoon platform, a closed automated system for patient-scale cell therapy manufacturing; and specialty raw materials and enabling technology solutions in cell and gene therapy, injectable drugs, vaccines, and bio-manufacturing markets. The Capsules & Health Ingredients segment offers capsules, dosage form solutions, and health ingredients for pharmaceutical and nutraceutical customers. Lonza Group AG was incorporated in 1897 and is headquartered in Basel, Switzerland.

Key Stats

• Today's Range: $72.18 to $73.01
• 50-Day Range: $57.21 to $72.86
• 52-Week Range: $52.23 to $73.01
• Volume: 122,656 shs
• Average Volume: 100,654 shs
• Market Capitalization: $52.62 billion
• P/E Ratio: N/A
• Dividend Yield: 0.26%
• Price Target: N/A
• Consensus Rating: Strong Buy

Lonza Group Stock Analysis - MarketRank™

Lonza Group scored higher than 22% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Lonza Group.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: 15.43%

Earnings Growth

Earnings for Lonza Group are expected to grow by 15.43% in the coming year, from $1.88 to $2.17 per share.

Price to Earnings Growth Ratio

Lonza Group has a PEG Ratio of 2.01. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Lonza Group has a P/B Ratio of 4.94. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.00% of the float of Lonza Group has been sold short.

Short Interest Ratio / Days to Cover

Lonza Group has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Lonza Group has recently increased by 618.75%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.8 / 5
• Dividend Strength: Weak

Dividend Yield

Lonza Group has a dividend yield of 0.27%, which is in the bottom 25% of all stocks that pay dividends.

Dividend Growth

Lonza Group does not have a long track record of dividend growth.

Dividend Sustainability

Based on earnings estimates, Lonza Group will have a dividend payout ratio of 8.76% next year. This indicates that Lonza Group will be able to sustain or increase its dividend.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.00% of the float of Lonza Group has been sold short.

Short Interest Ratio / Days to Cover

Lonza Group has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Lonza Group has recently increased by 618.75%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 1.4 / 5
• News Sentiment: N/A

News Sentiment

Lonza Group has a news sentiment score of 0.43. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.58 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Lonza Group this week, compared to 1 article on an average week.

Search Interest

Only 1 people have searched for LZAGY on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Lonza Group insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 0.07% of the stock of Lonza Group is held by insiders.

Percentage Held by Institutions

Only 0.04% of the stock of Lonza Group is held by institutions.

LZAGY Stock Analysis - Frequently Asked Questions

How have LZAGY shares performed this year?

Lonza Group's stock was trading at $58.78 at the beginning of the year. Since then, LZAGY shares have increased by 24.0% and is now trading at $72.86.
View the best growth stocks for 2025 here.

Does Lonza Group have any subsidiaries?

Lonza Group subsidiaries include Octane Biotech, Micro-Macinazione, Capsugel, PharmaCell, InterHealth Nutraceuticals, Triangle Research Labs, Diacon Technologies, and others.

How do I buy shares of Lonza Group?

Shares of LZAGY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Today: 5/04/2025
• Next Earnings (Estimated): 7/23/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Tobacco products
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:LZAGY
• CIK: 1446711
• Web: www.lonza.com
• Phone: (161) 316-8111
• Fax: 41-61-316-9111
• Employees: 18,000
• Year Founded: 1897

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: 38.76
• P/E Growth: 2.01
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: 0.45
• Current Ratio: 1.52
• Quick Ratio: 1.38

Sales & Book Value

• Annual Sales: $7.47 billion
• Price / Sales: 7.05
• Cash Flow: $2.24 per share
• Price / Cash Flow: 32.54
• Book Value: $14.76 per share
• Price / Book: 4.94

Miscellaneous

• Outstanding Shares: 722,262,000
• Free Float: 721,756,000
• Market Cap: $52.62 billion
• Optionable: Not Optionable
• Beta: 1.17